tilsotolimod   Click here for help

GtoPdb Ligand ID: 14712

Synonyms: IMO-2125 | IMO2125
Immunopharmacology Ligand
Compound class: Nucleic acid
Comment: Tilsotolimod (IMO-2125) is a phosphorothioate (P-thio) CpG oligonucleotide that is intended to act as a Toll-like receptor 9 (TLR9) agonist. Structurally it is a symmetrical, dual-strand 3'-3'-linked molecule.

Full sequence is :
O,O'-(2-hydroxypropane-1,3-diyl) bis(hydrogen all-P-ambo-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thio-3'-guanylate)
No information available.
Summary of Clinical Use Click here for help
Tilsotolimod (IMO-2125) was progressed as a clinical candidate with potential to induce an anti-tumour immune response. The phase 3 ILLUMINATE-301 study was terminated due to lack of efficacy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04126876 A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma Phase 2 Interventional Amsterdam UMC, location VUmc
NCT03445533 A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma Phase 3 Interventional Idera Pharmaceuticals, Inc. The ILLUMINATE-301 study 1